Integra LifeSciences
IART
144 hedge funds and large institutions have $1.21B invested in Integra LifeSciences in 2013 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 66 increasing their positions, 33 reducing their positions, and 11 closing their positions.
118% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 11
100% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 33
35% more capital invested
Capital invested by funds: $893M → $1.21B (+$313M)
10% more funds holding
Funds holding: 131 → 144 (+13)
2% less call options, than puts
Call options by funds: $1.67M | Put options by funds: $1.71M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$40.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.9M |
| 3 |
DM
Deerfield Management
New York
|
+$12.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.93M |
| 5 |
NAM
Netols Asset Management
Mequon,
Wisconsin
|
+$8.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Barings
Charlotte,
North Carolina
|
-$9.52M |
| 2 |
BC
Broadfin Capital
New York
|
-$8.91M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.18M |
| 4 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
-$2.17M |
| 5 |
Boston Partners
Boston,
Massachusetts
|
-$1.84M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SSG
151
Summit Securities Group
New York
| – | -$12K | -734 | Closed |
|
|
PAM
152
Panagora Asset Management
Boston,
Massachusetts
| – | -$8K | -467 | Closed |
|
153
Envestnet Asset Management
Chicago,
Illinois
| – | -$587 | -32 | -76% |
|
|
MFS
154
MSI Financial Services
Springfield,
Massachusetts
| – | +$220 | +12 | New |
|
IART Hedge Fund Activity: Q4 2013 in Review
144 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q4 2013, worth a combined $1.21B — up 35% from $893M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new IART positions and 11 closed out — a net gain of 13 holders — while 66 added to existing stakes and 33 trimmed.
The largest buyer was Wells Fargo, adding an estimated $40.2M. The largest seller was Barings, cutting an estimated $9.52M.
- 144 institutional investors held Integra LifeSciences (IART) as of Q4 2013, up from 131 in Q3 2013.
- Funds reported $1.21B of Integra LifeSciences stock for Q4 2013, up 35% quarter-over-quarter.
- 24 funds opened new Integra LifeSciences positions in Q4 2013 and 11 closed out, a net change of +13 holders.
- The largest Integra LifeSciences buyer in Q4 2013 was Wells Fargo, an estimated $40.2M added.
- The largest Integra LifeSciences seller in Q4 2013 was Barings, an estimated $9.52M sold.
Based on aggregated 13F filings for Q4 2013.